Compumedics Stock

Compumedics EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Compumedics (CMP.AX) as of Jun 24, 2026 is 64.66.In the previous year, EV/EBIT (Enterprise Value to EBIT) was -636.6 — a change of -110.16% (higher).

EV/EBIT

64.66

YoY

-110.16%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Compumedics is 2026 64.66 . EV/EBIT (Enterprise Value to EBIT) of Compumedics was 2025 -636.6 . It decreases by -110.16% higher compared to the previous year.

The Compumedics EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2006
-1,821 base
Jan 1, 2007
1,067 base
Jan 1, 2008
816 base
Jan 1, 2009
721 base
Jan 1, 2010
1,399 base
Jan 1, 2011
985 base
Jan 1, 2012
-929 base
Jan 1, 2013
-1,590 base
Jan 1, 2014
949 base
Jan 1, 2015
2,642 base
Jan 1, 2016
4,574 base
Jan 1, 2017
5,247 base
Jan 1, 2018
1,918 base
Jan 1, 2019
2,650 base
Jan 1, 2020
-26,924 base
YEARPRICE-TO-EBIT
2026 est 9,90
2025 70,39
2024 -515,91
2023 -16,43
2022 35,90
2021 68,50
2020 -269,24
2019 26,50
2018 19,18
2017 52,47
2016 45,74
2015 26,42
2014 9,49
2013 -15,90
2012 -9,29
2011 9,85
2010 13,99
2009 7,21
2008 8,16
2007 10,67
2006 -18,21
Access this data via the Eulerpool API
Get Free API Key

Compumedics Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Compumedics's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Compumedics's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Compumedics's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Compumedics grows earnings faster than its peers.

Compumedics Stock analysis

What does Compumedics do? Compumedics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Compumedics stock

EV/EBIT (Enterprise Value to EBIT) of Compumedics amounted to -636.6 64.66

Access this data via the Eulerpool API
Get Free API Key

Valuation — Compumedics

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Compumedics